Check-cap ltd. announces $35 million registered direct offering

Isfiya, israel, june 30, 2021 /prnewswire/ -- check-cap ltd. (the "company" or "check-cap") (nasdaq: chek), (nasdaq: chekz), a clinical stage medical diagnostics company advancing the development of c-scan®, the first and only patient-friendly, preparation-free screening test, to detect polyps before they may transform into colorectal cancer (crc), today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 25,925,926 of the company's ordinary shares and accompanying short-term warrants to purchase up to an aggregate of 25,925,926 of the company's ordinary shares in a registered direct offering.
CHEK Ratings Summary
CHEK Quant Ranking